Ai Platform
7 stories covering ai platform — fund closes, LP allocations, regulatory filings, deal flow, and fundraising signals from PipelineRoad's editorial team.
Transgene and NEC Bio Sign License Agreement for TG4050 Development
Transgene and NEC Bio have signed a license agreement to advance TG4050 for head and neck cancer, involving payments in shares and cash.
Transgene and NEC Bio Sign License for TG4050 Development in Head and Neck Cancers
Transgene and NEC Bio announced a license agreement on April 2, 2026, for advancing TG4050, a personalized vaccine for HPV-negative head and neck cancers, including financial payments to NEC.
Transgene and NEC Bio Sign License for TG4050 Development
Transgene and NEC Bio have signed a license agreement to advance TG4050 for HPV-negative head and neck cancer treatment, including financial payments.
Transgene and NEC Bio Sign License for TG4050 in Head and Neck Cancer
Transgene and NEC Bio have signed a license agreement to advance TG4050's development for resected HPV-negative head and neck cancer, including financial terms like a €2.5 million technology access fe
Yatiri Bio Enters Exclusive Option Agreement for Denfivontinib with Oscotec
Yatiri Bio announces an exclusive global option to license denfivontinib from Oscotec for AML treatment, using its AI-driven platform.
Red Light Holland Engages Kala Bio's AI for PEX010 Development
Red Light Holland has engaged Kala Bio's Researgency.ai platform to advance the clinical development of Filament's PEX010 psilocybin drug candidate, as announced on March 18, 2026.
Red Light Holland Engages Kala Bio’s AI for PEX010 Psilocybin Development
Red Light Holland has engaged Kala Bio’s Researgency.ai platform to advance the clinical development of Filament’s PEX010 botanical psilocybin drug candidate, as per a March 18, 2026 announcement.
